Neumora Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Neumora Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2022 to Q3 2024.
  • Neumora Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$72.5M, a 36.8% decline year-over-year.
  • Neumora Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$294M, a 89.1% decline year-over-year.
  • Neumora Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$236M, a 80.2% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$294M -$72.5M -$19.5M -36.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$274M -$58.7M -$20.2M -52.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$254M -$53.7M -$18.1M -50.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$236M -$109M -$80.6M -286% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$155M -$53M -$23.7M -80.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$132M -$38.5M -$8.17M -26.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$123M -$35.6M +$7.42M +17.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$131M -$28.1M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$29.3M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$30.4M Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-01
Q1 2022 -$43M Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.